MISSISSAUGA, Ontario, September 18, 2012 – CML HealthCare Inc. (TSX: CLC) (the “Company” or “CML”) and MaRS Innovation (MI), a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in medical diagnostics.
This story was covered in the Globe and Mail, Canadian Business, 680 News, Reuters, Sympatico.ca, the Huffington Post Canada, Technology Trasnfer Tactics, and the Winnipeg Free Press, among others. It was distributed via Yahoo! Finance, Healthcare Global.com, marketwire ...
MaRS Innovation (MI), The Hospital for Sick Children (SickKids) and NovoTek Therapeutics Inc. (NovoTek) have announced a strategic partnership to co‐develop, and bring to the Chinese market, a novel therapeutic cream aimed at reducing scar formation post surgery.
This project was covered in The Globe and Mail on May 7, 2012.
TORONTO (May 31, 2011) — MaRS Innovation (MI) and GlaxoSmithKline Inc. (GSK) today announced a new development fund — the GSK-MaRS Innovation Fund — that will support and fast-track the commercialization of some of the country’s most promising translational research coming from 16 leading academic health sciences centres, hospitals and universities derived from MI’s member institutions.
“From the discovery of insulin in 1922 to the discovery of stem cells, Ontario has a rich, proud history of world-class medical and scientific breakthroughs,” said ...
MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life sciences technologies during the early stages of pharmaceutical and medical device development.
The Translational Innovation Partnership Program (TIPP) is the first co-funding agreement of its kind for MI. (more…)
TORONTO, ON and VANCOUVER, BC (November 30, 2009) - MaRS Innovation (MI) and the Centre for Drug Research and Development (CDRD) are pleased to announce that they have entered into an agreement to collaborate on projects of mutual interest with a goal to advance and commercialize early-stage health-related discoveries.
“We are excited about our partnership with the CDRD as it provides an opportunity for the two organizations to augment each other’s strengths, and leverage resources to generate attractive packages for potential partners, thereby supporting both of our organizations’ ...